Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targeted antibody ventures Mersana and CytomX attract venture dollars amid partnering promise

This article was originally published in Scrip

Executive Summary

Companies on opposite US coasts announced venture capital funding on 31 July to boost next-generation targeted discovery and development platforms. Cambridge, Massachusetts-based antibody-drug conjugate (ADC) specialist Mersana Therapeutics raised $27 million in a Series A-1 round and CytomX Therapeutics in San Francisco increased its Series B round to $41 million for its tissue-specific antibodies.

You may also be interested in...



VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs

During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.

Bristol’s CAR-T Strategy Comes Into Focus With Two Near-Term Filings

In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.

J&J Quickly Advances BCMA-Targeting CAR-T As JNJ-4528 Shows 100% Response

Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.

Topics

Related Companies

UsernamePublicRestriction

Register

SC018316

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel